Cardlytics, Inc. (CDLX) Stock Price & Analysis

Cardlytics, Inc. (CDLX) fell 8.46% to USD 4.76 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.

CDLX last closed at USD 5.2; the session ranged USD 4.5–5.2 on volume of 196,160 shares. Market capitalization is $27.65M, with a 52-week range of USD 4.5–32.8 (NGM). Source: Nexqual, June 9, 2026 at 23:49 UTC.

Key Statistics (as of June 9, 2026 at 23:49 UTC)

PriceUSD 4.76
Change▼ 8.46% (down)
Previous CloseUSD 5.2
OpenUSD 5.2
Day RangeUSD 4.5 – 5.2
52-Week RangeUSD 4.5 – 32.8
Volume196,160 shares
Market Cap$27.65M
ExchangeNGM

Technical Analysis (CDLX)

Nexqual's technical model rates CDLX "SELL" based on 3 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.

Overall SignalSELL
RSI (14)19.14 (oversold)
vs SMA50Below (USD 8.24)
MACD-0.69 (negative)

Analyst Ratings (CDLX)

Wall Street analysts rate CDLX "Hold" based on 4 analysts, with a mean price target of USD 10.75 (range USD 8–15), per Nexqual as of June 9, 2026 at 23:49 UTC.

Consensus RatingHold
Analyst Count4
Mean TargetUSD 10.75
High TargetUSD 15
Low TargetUSD 8
Buy / Hold / Sell0 / 4 / 1

Earnings (CDLX)

Next Earnings Date2026-08-05
EPS EstimateUSD -1.07
Revenue Estimate$36.89M

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD -1.1 vs est -2.13 ▲ beat
2025-12-31USD 0.3 vs est -0.7 ▲ beat
2025-09-30USD -0.7 vs est -1.5 ▲ beat
2025-06-30USD -1.3 vs est -1.63 ▲ beat

Source: Nexqual, June 9, 2026 at 23:49 UTC.

Financials & Fundamentals (CDLX)

Total Revenue$211.16M
Revenue Growth (YoY)-44.60%
Gross Margin+47.46%
Operating Margin-24.11%
Profit Margin-44.84%
ROE-356.04%
Current Ratio2.17
Total Cash$59.80M
Total Debt$210.03M
Free Cash Flow$19.05M

Source: Nexqual, June 9, 2026 at 23:49 UTC.

Financial Health Score (CDLX)

Nexqual rates Cardlytics, Inc.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:49 UTC.

GrowthCritical — Revenue -16% YoY (annual), sharp decline
ProfitabilityMixed — Gross margin 47%, operating -24%
Balance SheetMixed — $60M cash vs $210M debt
Cash FlowSolid — FCF $19M, 8% margin
EfficiencyCritical — ROE -356%, ROA -7.7%

Ownership (CDLX)

Insider Ownership+4.60%
Institutional Ownership+29.90%
Shares Outstanding5.81M
Float49.88M
Short % of Float+13.87%

Source: Nexqual, June 9, 2026 at 23:49 UTC.

Leadership (CDLX)

Cardlytics, Inc. is led by Amit Gupta (age 52), CEO & Director, per Nexqual as of June 9, 2026 at 23:49 UTC.

CEO & DirectorAmit Gupta (age 52)
Chief Financial OfficerDavid Evans
Chief Technology OfficerPeter Chan
Chief Product OfficerJose Singer

Major Backers & Investors (CDLX)

Notable institutional backers of Cardlytics, Inc. include CAS Investment Partners, LLC, 683 Capital Management LLC, KPS Global Asset Management UK Limited, according to Nexqual as of June 9, 2026 at 23:49 UTC.

Active Investors

InvestorStake
CAS Investment Partners, LLC8.95%
683 Capital Management LLC2.5%
KPS Global Asset Management UK Limited2.1%
Worldly Partners Management, LLC 1.99%
RBF Capital, LLC1.38%
Fidelity0.92%
Quinn Opportunity Partners, LLC0.8%

Index Funds (Passive)

FundStake
Vanguard Group7.4%
BlackRock1.94%
Geode Capital1.26%

Source: Nexqual, June 9, 2026 at 23:49 UTC.

From Cardlytics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)

Key Strengths & Strategy (as disclosed to the SEC)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
EVEREverQuote, Inc.USD 19.39▲ 0.36%
KODKodiak Sciences IncUSD 31.06▲ 0.03%
DOMODomo, Inc.USD 3.29▼ 3.52%
CARGCarGurus, Inc.USD 28.26▲ 3.06%
SPTSprout Social, IncUSD 6.96▼ 3.73%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.